W.H. van der Laan

Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial

J. W. J. Bijlsma, Paco M J Welsing, Thasia Woodworth et al. · The Lancet · 2016 · 246 citations

Life Sciences, Immunology, Pharmacotherapy +11

Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar Infliximab

Lieke Tweehuysen, Bart J. F. van den Bemt, Iris L. van Ingen et al. · Arthritis & Rheumatology · 2017 · 164 citations

Medicine, Internal Medicine, Pharmacotherapy +16

Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3

W.H. van der Laan, Paul H.A. Quax, Christian A. Seemayer et al. · Gene Therapy · 2003 · 115 citations

Medicine, Orthopaedic Surgery, Orthopedic Surgery +16

Human granzyme B mediates cartilage proteoglycan degradation and is expressed at the invasive front of the synovium in rheumatoid arthritis

H. K. Ronday, W.H. van der Laan, Paul P. Tak et al. · Lara D. Veeken · 2001 · 83 citations

Medicine, Immunology, Pathology +17

Non-adherence to disease-modifying antirheumatic drugs is associated with higher disease activity in early arthritis patients in the first year of the disease

Annelieke Pasma, Charlotte Schenk, Reinier Timman et al. · Arthritis Research & Therapy · 2015 · 75 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +16